Sunday, September 23, 2012

Novartis - Phase III study show that RLX030 reduced deaths in patients with acute heart failure

The double blind placebo controlled study RELAX-AHF enrolled 1161 paitents with Acute heart failure.  The study was evaluating the efficacy of RLX030, which is one of the first in new class of medicines. RLX030 is a recombinant form of the human hormone relaxin-2 which occurs naturally in both men and women. 
The study had two primary endpoints using different scales to measure reduction in dyspnea, only one of which reached statistical significance.  Over six months, RLX030 also reduced all cause mortality in patients with acute heart failure.